Metsera clinical trials
Acquired by Pfizer, Nov 13, 2025 · source ↗
The registry lists 1 studies whose lead sponsor is Metsera. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 28, 2026.
- 1study on the registry
- 0open to participants now
Before and after it joined Pfizer
- First submitted before Metsera became part of Pfizer
- 1
- First submitted after Metsera became part of Pfizer
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Metsera’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 1
All 1 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed1100%
Over the years
- 124
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Metsera, a wholly owned subsidiary of Pfizer1 study
Something wrong with this grouping? Tell us on the Pfizer page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All Pfizer studies →
- This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or ObesityCompletedNCT06857617Phase 1/2
Sponsor listed in the registry: Metsera, a wholly owned subsidiary of Pfizer · First submitted before Metsera became part of Pfizer